Biotech Values

[biopharm]

This is an odd partnership insofar as BMY and JNJ each have big-selling anticoagulant drugs (Eliquis and Xarelto, respectively) whose sales could be cannibalized by BMS-986177 if FXIa inhibition turns out to be a better MoA for anticoagulation than FXa inhibition.

On the other hand, by the time BMS-986177 gets to market, there won’t be much patent life remaining on Eliquis or Xarelto, so BMS-986177 could be considered a lifecycle management program for both BMY and JNJ (but not for PFE and Bayer, who co-own Eliquis and Xarelto, respectively).

Odd indeed

Must be lots of drugs and relative MOAs on the line and Biomarkers would be of upmost importance